Biotech · Public company · Dallas, TX, US

Lantern Pharma Inc.

Ticker LTRN · SEC CIK 0001763950

Track this companyFree. Adds Lantern Pharma Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials33 recruiting or active

Pipeline programs7From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline7

CarboplatinPhase 2 · Adenocarcinoma of LungClinicalTrials.gov · fetched Nov 12, 2026
LP-184Phase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
LP-300Phase 2 · Adenocarcinoma of LungClinicalTrials.gov · fetched Nov 12, 2026
Nivolumab & IpilimumabPhase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
OlaparibPhase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
PemetrexedPhase 2 · Adenocarcinoma of LungClinicalTrials.gov · fetched Nov 12, 2026
LP-284Phase 1 · Relapsed or Refractory LymphomasClinicalTrials.gov · fetched Nov 12, 2026

Study of LP-184 in Patients With Advanced Solid TumorsPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Jun 9, 2023ClinicalTrials.gov NCT05933265 · fetched Nov 12, 2026
A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung AdenocarcinomaPHASE2 · RECRUITING · started Mar 1, 2023ClinicalTrials.gov NCT05456256 · fetched Nov 12, 2026
Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid TumorsPHASE1 · RECRUITING · started Jan 3, 2023ClinicalTrials.gov NCT06132503 · fetched Nov 12, 2026